Sagimet Biosciences (SGMT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $8.17, +8.28% vs the prior close of $7.55.
- Volume 1.37M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SGMT jumps 8.3% to $8.17. Closed at $8.17, +8.28% vs the prior close of $7.55. Day range $7.54–$8.27, opened at $7.61.
SGMT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — SGMT jumps 8.3% to $8.17
- Closed at $8.17, +8.28% vs the prior close of $7.55. Day range $7.54–$8.27, opened at $7.61.
- Volume was 1.37M shares, 1.0x its 50-day average of 1.35M.
- Price is -17.9% vs its 50-day average ($9.95) and +12.1% vs its 200-day average ($7.28).
- 52-week range $4.50–$11.45; today's close sits at 53% of that range, 28.6% below the 52-week high.
Oct 14, 2026 — SGMT slides 5.5% to $7.55, a 1-month low, 3 down days in a row
- Closed at $7.55, -5.45% vs the prior close of $7.98. Day range $7.51–$8.00, opened at $7.78.
- Volume was 1.98M shares, 1.5x its 50-day average of 1.35M.
- Price is -24.2% vs its 50-day average ($9.96) and +3.7% vs its 200-day average ($7.27).
- 52-week range $4.50–$11.45; today's close sits at 44% of that range, 34.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — SGMT slides 9.3% to $7.98, a 1-month low
- Closed at $7.98, -9.32% vs the prior close of $8.80. Day range $7.88–$8.74, opened at $8.70.
- Volume was 2.35M shares, 1.7x its 50-day average of 1.36M.
- Price is -19.9% vs its 50-day average ($9.96) and +9.8% vs its 200-day average ($7.27).
- 52-week range $4.50–$11.45; today's close sits at 50% of that range, 30.3% below the 52-week high.
Oct 12, 2026 — SGMT dips 1.5% to $8.80
- Closed at $8.80, -1.46% vs the prior close of $8.93. Day range $8.73–$9.15, opened at $8.85.
- Volume was 1.16M shares, 0.9x its 50-day average of 1.35M.
- Price is -11.5% vs its 50-day average ($9.95) and +21.3% vs its 200-day average ($7.26).
- 52-week range $4.50–$11.45; today's close sits at 62% of that range, 23.1% below the 52-week high.
Oct 9, 2026 — SGMT ends flat (+0.1%) to $8.93, 3 up days in a row
- Closed at $8.93, +0.11% vs the prior close of $8.92. Day range $8.78–$9.05, opened at $8.84.
- Volume was 763.50K shares, 0.6x its 50-day average of 1.34M — lighter than usual.
- Price is -9.9% vs its 50-day average ($9.91) and +23.3% vs its 200-day average ($7.24).
- 52-week range $4.50–$11.45; today's close sits at 64% of that range, 22.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — SGMT rises 0.5% to $8.92
- Closed at $8.92, +0.45% vs the prior close of $8.88. Day range $8.63–$8.94, opened at $8.80.
- Volume was 1.23M shares, 0.9x its 50-day average of 1.33M.
- Price is -9.7% vs its 50-day average ($9.88) and +23.4% vs its 200-day average ($7.23).
- 52-week range $4.50–$11.45; today's close sits at 64% of that range, 22.1% below the 52-week high.
Oct 7, 2026 — SGMT rises 1.4% to $8.88
- Closed at $8.88, +1.37% vs the prior close of $8.76. Day range $8.60–$8.97, opened at $8.65.
- Volume was 631.60K shares, 0.5x its 50-day average of 1.32M — lighter than usual.
- Price is -9.8% vs its 50-day average ($9.84) and +23.1% vs its 200-day average ($7.22).
- 52-week range $4.50–$11.45; today's close sits at 63% of that range, 22.4% below the 52-week high.
Oct 6, 2026 — SGMT dips 3.0% to $8.76, a 1-month low, 4 down days in a row
- Closed at $8.76, -2.99% vs the prior close of $9.03. Day range $8.55–$8.99, opened at $8.99.
- Volume was 896.30K shares, 0.7x its 50-day average of 1.31M.
- Price is -10.7% vs its 50-day average ($9.81) and +21.7% vs its 200-day average ($7.20).
- 52-week range $4.50–$11.45; today's close sits at 61% of that range, 23.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — SGMT dips 1.2% to $9.03, a 1-month low, 3 down days in a row
- Closed at $9.03, -1.20% vs the prior close of $9.14. Day range $8.40–$9.12, opened at $9.07.
- Volume was 1.53M shares, 1.2x its 50-day average of 1.30M.
- Price is -7.7% vs its 50-day average ($9.79) and +25.6% vs its 200-day average ($7.19).
- 52-week range $4.50–$11.45; today's close sits at 65% of that range, 21.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — SGMT dips 2.5% to $9.14
- Closed at $9.14, -2.45% vs the prior close of $9.37. Day range $8.88–$9.38, opened at $9.26.
- Volume was 1.71M shares, 1.3x its 50-day average of 1.28M.
- Price is -6.2% vs its 50-day average ($9.75) and +27.4% vs its 200-day average ($7.17).
- 52-week range $4.50–$11.45; today's close sits at 67% of that range, 20.2% below the 52-week high.
SGMT latest news & SEC filings
Every SEC filing by or about SGMT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Oct 1, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 30, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kemble George sold 350,987 shares at $10.23 (≈$3.59M) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kemble George sold 20,206 shares at $9.95 (≈$201.05K) on Aug 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$13.95M (prior year -$10.39M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.26 (prior year -$0.32) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Happel David sold 64,051 shares at $7.76 (≈$497.04K) on Jul 20, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade SGMT
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Apr 27, 2026, Mar 11, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.20% (largest 12.6%). That is a volatile stock.
- Liquidity: about 1.64M shares (≈$13.42M) trade per day on average.
- 52-week position: $8.17 vs a range of $4.50–$11.45 (53% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 10 sales; latest: George Kemble sold 350,987 shares on Aug 14, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 30, 2026; 8-K Aug 13, 2026.
- Share count: 30.67M shares outstanding (Nov 8, 2024), +43.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SGMT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 7.61 | 8.27 | 7.54 | 8.17 | 1.37M |
| Oct 14, 2026 | 7.78 | 8.00 | 7.51 | 7.55 | 1.98M |
| Oct 13, 2026 | 8.70 | 8.74 | 7.88 | 7.98 | 2.35M |
| Oct 12, 2026 | 8.85 | 9.15 | 8.73 | 8.80 | 1.16M |
| Oct 9, 2026 | 8.84 | 9.05 | 8.78 | 8.93 | 763.50K |
| Oct 8, 2026 | 8.80 | 8.94 | 8.63 | 8.92 | 1.23M |
| Oct 7, 2026 | 8.65 | 8.97 | 8.60 | 8.88 | 631.60K |
| Oct 6, 2026 | 8.99 | 8.99 | 8.55 | 8.76 | 896.30K |
| Oct 5, 2026 | 9.07 | 9.12 | 8.40 | 9.03 | 1.53M |
| Oct 2, 2026 | 9.26 | 9.38 | 8.88 | 9.14 | 1.71M |
| Oct 1, 2026 | 9.63 | 10.01 | 9.31 | 9.37 | 2.01M |
| Sep 30, 2026 | 10.61 | 10.93 | 9.46 | 9.88 | 5.45M |
| Sep 29, 2026 | 9.92 | 9.92 | 9.25 | 9.33 | 856.80K |
| Sep 28, 2026 | 9.15 | 9.95 | 9.02 | 9.94 | 1.35M |
| Sep 25, 2026 | 9.11 | 9.27 | 8.89 | 9.24 | 1.25M |
| Sep 24, 2026 | 9.78 | 9.99 | 8.69 | 9.11 | 3.72M |
| Sep 23, 2026 | 11.23 | 11.26 | 10.15 | 10.42 | 1.12M |
| Sep 22, 2026 | 10.84 | 11.33 | 10.72 | 11.09 | 874.10K |
| Sep 21, 2026 | 11.20 | 11.21 | 10.65 | 10.80 | 753.30K |
| Sep 18, 2026 | 11.16 | 11.40 | 10.80 | 11.09 | 1.85M |
About Sagimet Biosciences
Sagimet Biosciences (SGMT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FOSTER CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1400118.
SGMT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Elizabeth A Grammer | Director | Jun 15, 2026 |
| David Happel | President & CEO | Jul 22, 2026 |
| Paul W. Hoelscher | Director | Jun 15, 2026 |
| Jennifer Jarrett | Director | Jun 15, 2026 |
| George Kemble | Director | Aug 17, 2026 |
| Anne M. Phillips | Director | Jun 15, 2026 |
| Beth C Seidenberg | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thierry Chauche | Chief Financial Officer | Jun 1, 2026 |
| Andreas Grauer | Chief Medical Officer | Jun 1, 2026 |
| David Happel | President & CEO | Jul 22, 2026 |
| Eduardo Bruno Martins | Chief Medical Officer | Feb 20, 2026 |
| Elizabeth Rozek | Chief Legal & Admin. Officer | Jul 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | George Kemble | Sale | 350,987 | $10.23 |
| Aug 11, 2026 | George Kemble | Sale | 20,206 | $9.95 |
| Jul 20, 2026 | David Happel | Sale | 64,051 | $7.76 |
| Jul 20, 2026 | George Kemble | Sale | 18,844 | $7.46 |
| Jul 20, 2026 | Elizabeth Rozek | Sale | 10,545 | $7.76 |
| Feb 10, 2026 | Eduardo Bruno Martins | Sale | 3,640 | $5.36 |
| Feb 10, 2026 | David Happel | Sale | 12,101 | $5.36 |
| Feb 10, 2026 | Elizabeth Rozek | Sale | 2,622 | $5.36 |
| Feb 10, 2026 | Thierry Chauche | Sale | 1,312 | $5.36 |
| Nov 20, 2025 | George Kemble | Sale | 37,688 | $7.69 |
SGMT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-51.04M | -1.58 | $-45.65M |
| Dec 31, 2024 | — | $-45.57M | -1.45 | $-42.44M |
| Dec 31, 2023 | $2.00M | $-27.88M | -2.66 | $-23.77M |
| Dec 31, 2022 | — | $-30.50M | -165.20 | $-24.49M |
Latest balance sheet: total assets $263.43M, total liabilities $7.28M, cash $165.90M (as of Jun 30, 2026).
SGMT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $9.52 |
| May 12, 2026 | 8-K Item 2.02 (results) | $7.65 |
| Apr 27, 2026 | 8-K Item 2.02 (results) | $8.12 |
| Mar 11, 2026 | 8-K Item 2.02 (results) | $5.74 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $7.74 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $9.58 |
| May 8, 2025 | 8-K Item 2.02 (results) | $3.20 |
| Mar 12, 2025 | 8-K Item 2.02 (results) | $3.51 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $5.18 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on SGMT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.